Chronic lymphocytic leukaemia
RecruitingStudy on Acalabrutinib and Obinutuzumab vs. Venetoclax and Obinutuzumab for Newly Diagnosed Chronic Lymphocytic Leukemia Patients
Study on Acalabrutinib and Obinutuzumab vs. Venetoclax and Obinutuzumab for Newly Diagnosed Chronic Lymphocytic Leukemia Patients
- Disease:Chronic lymphocytic leukaemia
- Substances:AcalabrutinibObinutuzumab+1
Poland- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego







